Access the full text.
Sign up today, get DeepDyve free for 14 days.
D Slamon, W Eiermann, N Robert (2016)
Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ earlyCancer Res, 76
C. Barcenas, S. Hurvitz, J. Palma, R. Bose, A. Chien, N. Iannotti, G. Marx, A. Brufsky, A. Litvak, E. Ibrahim, R. Alvarez, M. Ruiz-Borrego, N. Chan, Y. Manalo, A. Kellum, M. Trudeau, M. Thirlwell, J. Saenz, D. Hunt, R. Bryce, L. Mcculloch, H. Rugo, Debu Tripathy, A. Chan, L. Carcas, A. Castrellon, D. Chan, K. Cheong, B. Choi, M. Coleman, A. Conlin, R. Dichmann, D. Ellison, N. Erickson, I. Gore, Vincent Hansen, D. Huang, D. Hufnagel, F. Kass, S. Kendall, M. Kozloff, W. Lawler, K. Nahum, B. Pistilli, E. Reyes, J. Seeger, R. Somer, E. Chiu, G. Thomas, K. Tkaczuk, I. Vaziri, J. Wade, M. Wilkinson (2020)
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.Annals of oncology : official journal of the European Society for Medical Oncology
L. Gianni, W. Eiermann, V. Semiglazov, A. Lluch, S. Tjulandin, M. Zambetti, A. Moliterni, F. Vázquez, M. Byakhov, M. Lichinitser, M. Climent, E. Ciruelos, B. Ojeda, M. Mansutti, A. Bozhok, D. Magazzù, D. Heinzmann, J. Steinseifer, P. Valagussa, J. Baselga (2014)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.The Lancet. Oncology, 15 6
K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, G. Aktan, C. Ellis, A. Florance, S. Vukelja, J. Bischoff, J. Baselga, J. O’Shaughnessy (2012)
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
S Loibl, L Gianni (2017)
HER2-positive breast cancerLancet, 389
G. Minckwitz, M. Procter, E. Azambuja, D. Zardavas, M. Benyunes, G. Viale, T. Suter, A. Arahmani, N. Rouchet, E. Clark, A. Knott, I. Láng, C. Lévy, D. Yardley, J. Bines, R. Gelber, M. Piccart, J. Baselga (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2‐Positive Breast CancerThe New England Journal of Medicine, 377
J. Cortés, P. Fumoleau, G. Bianchi, T. Petrella, K. Gelmon, X. Pivot, S. Verma, J. Albanell, P. Conte, A. Lluch, S. Salvagni, V. Servent, L. Gianni, M. Scaltriti, G. Ross, J. Dixon, T. Szado, J. Baselga (2012)
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 14
P. Llovet, F. Illana, Lorena Martín-Morales, M. Hoya, P. Garre, M. Ibañez-Royo, P. Pérez-Segura, T. Caldés, V. García-Barberán (2017)
A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected familiesFamilial Cancer, 16
A. Brufsky, M. Mayer, H. Rugo, P. Kaufman, E. Tan-chiu, D. Tripathy, I. Tudor, Lisa Wang, M. Brammer, M. Shing, M. Yood, D. Yardley (2011)
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHERClinical Cancer Research, 17
S. Chia, M. Martín, H. Iwata, B. Moy, A. Lalani, F. Holmes, J. Mansi, G. Minckwitz, M. Buyse, S. Delaloge, B. Ejlertsen, B. Yao, A. Rosales, B. Hellerstedt, S. Cold, Kenichi Inoue, Z. Shen, T. Galeano, C. Barrios, A. Chan (2018)
Abstract P1-13-03: Effects of neratinib after trastuzumab-based adjuvant therapy in hormone receptor-positive HER2+ early-stage breast cancer: Exploratory analyses from the phase III ExteNET trialCancer Research, 78
G. Marx, A. Chien, J. García-Saenz, A. Chan, M. Ruiz-Borrego, C. Barcenas, M. Thirlwell, M. Trudeau, R. Bose, D. Egle, B. Pistilli, J. Wassermann, K. Cheong, D. Semsek, C. Singer, D. Hunt, Utpal Khambholja, Feng Xu, Naisargee Shah, A. Brufsky (2021)
Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.Journal of Clinical Oncology, 39
Clinical outcomes and treatment practice patterns of patients with HER 2 - positive metastatic
J. Mortimer, J. Palma, K. Schmid, Y. Ye, M. Jahanzeb (2019)
Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trialBreast Cancer Research : BCR, 21
A. Awada, R. Colomer, Kenichi Inoue, I. Bondarenko, R. Badwe, G. Demetriou, Soo-Chin Lee, A. Mehta, Sung-Bae Kim, T. Bachelot, C. Goswami, S. Deo, R. Bose, A. Wong, Feng Xu, B. Yao, R. Bryce, L. Carey (2016)
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.JAMA oncology, 2 12
D Slamon (2016)
10.1158/1538-7445.SABCS15-S5-04Cancer Res, 76
(NERLYNX® (neratinib) [package insert]. Puma Biotechnology, Inc, Los Angeles, CA, 2021)
NERLYNX® (neratinib) [package insert]. Puma Biotechnology, Inc, Los Angeles, CA, 2021NERLYNX® (neratinib) [package insert]. Puma Biotechnology, Inc, Los Angeles, CA, 2021, NERLYNX® (neratinib) [package insert]. Puma Biotechnology, Inc, Los Angeles, CA, 2021
S. Modi, C. Saura, T. Yamashita, Yeon-Hee Park, Sung-Bae Kim, K. Tamura, F. André, H. Iwata, Yoshinori Ito, J. Tsurutani, J. Sohn, N. Denduluri, C. Perrin, K. Aogi, E. Tokunaga, S. Im, K. Lee, S. Hurvitz, J. Cortés, Caleb Lee, Shuquan Chen, Lin Zhang, J. Shahidi, A. Yver, I. Krop (2019)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.The New England journal of medicine
Ryan Engel, V. Kaklamani (2012)
HER2-Positive Breast CancerDrugs, 67
E. Perez, E. Romond, V. Suman, Jong-Hyeon Jeong, G. Sledge, C. Geyer, S. Martino, P. Rastogi, J. Gralow, S. Swain, E. Winer, G. Colón-Otero, N. Davidson, E. Mamounas, J. Zujewski, N. Wolmark (2014)
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 33
R. Freedman, R. Gelman, C. Anders, M. Melisko, H. Parsons, Anne Cropp, Kelly Silvestri, Christine Cotter, K. Componeschi, Juan Marte, R. Connolly, B. Moy, C. Poznak, K. Blackwell, S. Puhalla, R. Jankowitz, K. Smith, N. Ibrahim, T. Moynihan, C. O'Sullivan, J. Nangia, P. Niravath, N. Tung, P. Pohlmann, Robyn Burns, M. Rimawi, I. Krop, A. Wolff, E. Winer, N. Lin (2019)
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain MetastasesJournal of Clinical Oncology, 37
R. Murthy, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. Hurvitz, N. Lin, V. Borges, V. Abramson, C. Anders, P. Bedard, Mafalda Oliveira, E. Jakobsen, T. Bachelot, S. Shachar, V. Müller, S. Braga, F. Duhoux, R. Greil, D. Cameron, L. Carey, G. Curigliano, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, M. Palanca-Wessels, L. Walker, W. Feng, E. Winer (2019)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.The New England journal of medicine
J. Sheng, C. Santa-Maria, N. Mangini, Haval Norman, R. Couzi, R. Nunes, M. Wilkinson, K. Visvanathan, R. Connolly, E. Torres, J. Fetting, D. Armstrong, Jessica Tao, L. Jacobs, J. Wright, Elissa Thorner, C. Hodgdon, S. Horn, A. Wolff, V. Stearns, K. Smith (2020)
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach.JCO oncology practice
G. Minckwitz, Chiun-Sheng Huang, M. Mano, S. Loibl, E. Mamounas, M. Untch, N. Wolmark, P. Rastogi, A. Schneeweiss, A. Redondo, H. Fischer, W. Jacot, A. Conlin, C. Arce‐Salinas, I. Wapnir, C. Jackisch, M. DiGiovanna, P. Fasching, J. Crown, P. Wülfing, Z. Shao, E. Caremoli, Haiyan Wu, L. Lam, D. Tesarowski, M. Smitt, Hannah Douthwaite, S. Singel, C. Geyer (2019)
Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast CancerThe New England Journal of Medicine, 380
(2020)
trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
S. Jacobs, A. Robidoux, J. Abraham, J. Peréz-García, N. Verde, J. Orcutt, M. Cazzaniga, F. Piette, S. Antolín, E. Aguirre, J. Cortés, A. Llombart-Cussac, S. Cosimo, Rim Kim, H. Feng, Corey Lipchik, P. Lucas, A. Srinivasan, Ying Wang, N. Song, P. Gavin, April Balousek, S. Paik, C. Allegra, N. Wolmark, K. Pogue-Geile (2019)
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerBreast Cancer Research : BCR, 21
L. Gianni, T. Pieńkowski, Y. Im, L. Tseng, Mei-Ching Liu, A. Lluch, E. Starosławska, J. Haba-Rodríguez, S. Im, J. Pedrini, B. Poirier, P. Morandi, V. Semiglazov, V. Srimuninnimit, G. Bianchi, D. Magazzù, V. Mcnally, Hannah Douthwaite, G. Ross, P. Valagussa (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.The Lancet. Oncology, 17 6
M. Gnant, H. Iwata, A. Bashford, R. Šeparović, A. Murias, E. Vicente, J. Means-Powell, I. Mayer, F. Senecal, R. Hui, R. Boer, J. Chiu, A. Armstrong, A. Ruíz, R. Bryce, Y. Ye, A. Chan (2018)
Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.Journal of Clinical Oncology, 36
PharmD Hicks, PhD Cope, Cha Novak, Rn Scherer (2017)
The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral OncolyticsJournal of the advanced practitioner in oncology, 8
E. Balogh, P. Ganz, Sharon Murphy, S. Nass, B. Ferrell, E. Stovall (2011)
Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an Institute of Medicine workshop.The oncologist, 16 12
Erin Olson, J. Najita, J. Sohl, A. Arnaout, H. Burstein, E. Winer, N. Lin (2013)
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.Breast, 22 4
(Untch M, Martin M, De Laurentiis M, Gligorov J. How to optimise extended adjuvant treatment with neratinib for patients with early HER2+ breast cancer. Oncol Ther. 2021. Online ahead of print. 10.1007/s40487-021-00153-5.)
Untch M, Martin M, De Laurentiis M, Gligorov J. How to optimise extended adjuvant treatment with neratinib for patients with early HER2+ breast cancer. Oncol Ther. 2021. Online ahead of print. 10.1007/s40487-021-00153-5.Untch M, Martin M, De Laurentiis M, Gligorov J. How to optimise extended adjuvant treatment with neratinib for patients with early HER2+ breast cancer. Oncol Ther. 2021. Online ahead of print. 10.1007/s40487-021-00153-5., Untch M, Martin M, De Laurentiis M, Gligorov J. How to optimise extended adjuvant treatment with neratinib for patients with early HER2+ breast cancer. Oncol Ther. 2021. Online ahead of print. 10.1007/s40487-021-00153-5.
H. Rugo, J. Palma, D. Tripathy, R. Bryce, S. Moran, E. Olek, L. Bosserman (2019)
The characterization, management, and future considerations for ErbB-family TKI-associated diarrheaBreast Cancer Research and Treatment, 175
S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh, V. Diéras, E. Guardino, L. Fang, Michael Lu, S. Olsen, K. Blackwell (2012)
Trastuzumab emtansine for HER2-positive advanced breast cancer.The New England journal of medicine, 367 19
JW Park, MC Liu, D Yee (2016)
Adaptive randomization of neratinib in early breast cancerN Engl J Med, 375
N. Lin, V. Borges, C. Anders, R. Murthy, E. Paplomata, E. Hamilton, S. Hurvitz, S. Loi, A. Okines, V. Abramson, Philippe Bédard, Mafalda Oliveira, V. Mueller, A. Zelnak, M. DiGiovanna, T. Bachelot, A. Chien, R. O'Regan, A. Wardley, A. Conlin, D. Cameron, L. Carey, G. Curigliano, K. Gelmon, S. Loibl, J. Mayor, S. McGoldrick, Xuebei An, E. Winer (2020)
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialJournal of Clinical Oncology, 38
D. Cameron, M. Piccart-Gebhart, R. Gelber, M. Procter, A. Goldhirsch, E. Azambuja, G. Castro, M. Untch, I. Smith, L. Gianni, J. Baselga, N. Al-Sakaff, S. Lauer, E. McFadden, B. Leyland-Jones, R. Bell, M. Dowsett, C. Jackisch (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialThe Lancet, 389
R. Freedman, R. Gelman, J. Wefel, M. Melisko, K. Hess, R. Connolly, C. Poznak, P. Niravath, S. Puhalla, N. Ibrahim, K. Blackwell, B. Moy, C. Herold, Minetta Liu, A. Lowe, N. Agar, N. Ryabin, Sarah Farooq, E. Lawler, M. Rimawi, I. Krop, A. Wolff, E. Winer, N. Lin (2016)
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 9
K. Blackwell, H. Burstein, A. Storniolo, H. Rugo, G. Sledge, M. Koehler, C. Ellis, M. Casey, S. Vukelja, J. Bischoff, J. Baselga, J. O’Shaughnessy (2010)
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers version 2
C. Saura, Mafalda Oliveira, Yin-Hsun Feng, M. Dai, Shang-Wen Chen, S. Hurvitz, Sung-Bae Kim, B. Moy, S. Delaloge, W. Gradishar, N. Masuda, M. Pálácova, M. Trudeau, J. Mattson, Y. Yap, M. Hou, M. Laurentiis, Yu-Min Yeh, Hong‐Tai Chang, T. Yau, H. Wildiers, B. Haley, D. Fagnani, Yen-Shen Lu, J. Crown, Johnson Lin, M. Takahashi, T. Takano, M. Yamaguchi, T. Fujii, B. Yao, J. Bebchuk, K. Keyvanjah, R. Bryce, A. Brufsky (2020)
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA TrialJournal of Clinical Oncology, 38
Trastuzumab emtansine for HER 2 - positive advanced breast can
Charles Geyer, J. Forster, D. Lindquist, Stephen Chan, C. Romieu, T. Pieńkowski, A. Jagiełło-Gruszfeld, J. Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, M. Campone, Neville Davidson, Mark Berger, C. Oliva, S. Rubin, S. Stein, David Cameron (2006)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.The New England journal of medicine, 355 26
J. Baselga, K. Gelmon, S. Verma, A. Wardley, P. Conte, D. Miles, G. Bianchi, J. Cortés, V. Mcnally, G. Ross, P. Fumoleau, L. Gianni (2010)
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
A. Schneeweiss, S. Chia, T. Hickish, V. Harvey, A. Eniu, M. Waldron-Lynch, J. Eng-Wong, S. Kirk, J. Cortés (2018)
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.European journal of cancer, 89
D. Cameron, M. Casey, M. Press, D. Lindquist, T. Pieńkowski, C. Romieu, S. Chan, A. Jagiełło-Gruszfeld, B. Kaufman, J. Crown, A. Chan, M. Campone, P. Viens, N. Davidson, V. Gorbounova, J. Raats, D. Skarlos, B. Newstat, D. Roychowdhury, P. Paoletti, C. Oliva, S. Rubin, S. Stein, C. Geyer (2008)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Research and Treatment, 112
F. Petrelli, M. Ghidini, V. Lonati, G. Tomasello, K. Borgonovo, M. Ghilardi, M. Cabiddu, S. Barni (2017)
The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.European journal of cancer, 84
(2019)
NSABP FB7: a phase II randomized neoadjuvant trial with paclitaxel ? trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2? breast cancer
A. Chan, S. Delaloge, F. Holmes, B. Moy, H. Iwata, V. Harvey, N. Robert, T. Silovski, E. Gokmen, G. Minckwitz, B. Ejlertsen, S. Chia, J. Mansi, C. Barrios, M. Gnant, M. Buyse, I. Gore, John Smith, G. Harker, N. Masuda, K. Petráková, Á. Zotano, N. Iannotti, G. Rodriguez, P. Tassone, A. Wong, R. Bryce, Y. Ye, B. Yao, Miguel Martín (2016)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology, 17 3
B. Moy, M. Takahashi, S. Ohtani, E. Chmielowska, N. Yamamoto, B. Coudert, Feng Xu, A. Wong, A. Chan (2021)
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.Journal of Clinical Oncology, 39
(2013)
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the posttrastuzumab era
D. Harrington, G. Parmigiani (2016)
Adaptive Randomization of Neratinib in Early Breast Cancer.The New England journal of medicine, 375 16
Miguel Martín, F. Holmes, B. Ejlertsen, S. Delaloge, B. Moy, H. Iwata, G. Minckwitz, S. Chia, J. Mansi, C. Barrios, M. Gnant, Z. Tomašević, N. Denduluri, R. Šeparović, E. Gokmen, A. Bashford, M. Borrego, Sung-Bae Kim, E. Jakobsen, A. Cicėnienė, Kenichi Inoue, F. Overkamp, J. Heijns, A. Armstrong, J. Link, A. Joy, R. Bryce, A. Wong, S. Moran, B. Yao, Feng Xu, A. Auerbach, M. Buyse, A. Chan (2017)
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology, 18 12
M. Untch, Miguel Martín, M. Laurentiis, J. Gligorov (2021)
How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast CancerOncology and Therapy, 9
(National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers version 2.2021. Published 8 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf)
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers version 2.2021. Published 8 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdfNational Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers version 2.2021. Published 8 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf, National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: central nervous system cancers version 2.2021. Published 8 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
(National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer version 8.2021. Published 13 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf)
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer version 8.2021. Published 13 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfNational Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer version 8.2021. Published 13 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf, National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer version 8.2021. Published 13 September 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
C. Jackisch, C. Barcenas, R. Bartsch, J. Palma, S. Glück, N. Harbeck, G. Macedo, J. O’Shaughnessy, B. Pistilli, M. Ruiz-Borrego, H. Rugo (2021)
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.Clinical breast cancer
IntroductionNeratinib and neratinib-based combinations have demonstrated efficacy for treatment of human epidermal growth factor receptor 2–positive (HER2+) early-stage and metastatic breast cancers. However, diarrhea has been reported as a common adverse event leading to neratinib discontinuation. Results from the CONTROL trial suggest that proactive diarrhea management with antidiarrheal prophylaxis or dose escalation of neratinib from a lower starting dose to the full FDA-approved dose of 240 mg/day can reduce the incidence, duration, and severity of neratinib-associated diarrhea in patients with early-stage breast cancer. Dose escalation has been included in the FDA-approved label for both early-stage and metastatic HER2+ breast cancer since June 2021.Case seriesThis series of five cases details real-world clinical implementation of strategies for management of neratinib-induced diarrhea in patients with early-stage and metastatic HER2+ breast cancer, including a patient with a pre-existing gastrointestinal disorder.Management and outcomeIn four of five cases, diarrhea was managed with neratinib dose escalation, and antidiarrheal prophylaxis with loperamide plus colestipol was used in the remaining case. Management of diarrhea allowed all patients to remain on therapy.DiscussionThis case series shows that neratinib-associated diarrhea can be managed effectively with neratinib dose escalation from a lower initial starting dose and/or prophylactic antidiarrheal medications in a real-world clinical setting. The findings highlight the importance of patient-provider communication in proactive management of adverse events. Widespread implementation of the strategies described here may improve adherence and thereby clinical outcomes for patients with HER2+ breast cancer treated with neratinib.
Oncology and Therapy – Springer Journals
Published: Jun 1, 2022
Keywords: Diarrhea; Early-stage breast cancer; HER2; Metastatic breast cancer; Neratinib
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.